In the past week, CLRB stock has gone down by -2.55%, with a monthly decline of -6.31% and a quarterly surge of 39.27%. The volatility ratio for the week is 7.58%, and the volatility levels for the last 30 days are 7.17% for Cellectar Biosciences Inc The simple moving average for the last 20 days is -5.24% for CLRB stock, with a simple moving average of 39.37% for the last 200 days.
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
The 36-month beta value for CLRB is also noteworthy at 0.92. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLRB is 11.13M, and at present, short sellers hold a 16.93% of that float. The average trading volume of CLRB on March 28, 2024 was 1.82M shares.
CLRB) stock’s latest price update
The stock price of Cellectar Biosciences Inc (NASDAQ: CLRB) has plunged by -5.58 when compared to previous closing price of 3.85, but the company has seen a -2.55% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-27 that Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of CLRB
ROTH Capital, on the other hand, stated in their research note that they expect to see CLRB reach a price target of $10. The rating they have provided for CLRB stocks is “Buy” according to the report published on January 21st, 2020.
CLRB Trading at -1.34% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.31% of loss for the given period.
Volatility was left at 7.17%, however, over the last 30 days, the volatility rate increased by 7.58%, as shares sank -7.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.76% lower at present.
During the last 5 trading sessions, CLRB fell by -2.55%, which changed the moving average for the period of 200-days by +98.09% in comparison to the 20-day moving average, which settled at $3.82. In addition, Cellectar Biosciences Inc saw 31.23% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CLRB
The total capital return value is set at -6.66. Equity return is now at value -536.81, with -225.65 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -53.06. The debt to equity ratio resting at -0.04. The interest coverage ratio of the stock is 262.07.
Currently, EBITDA for the company is -38.96 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
In summary, Cellectar Biosciences Inc (CLRB) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
